The LENT index predicts 30 day outcomes following hospitalization for heart failure by Van Spall, HG et al.
The LENT index predicts 30 day outcomes following
hospitalization for heart failure
Harriette GC Van Spall1,2,3* , Tauben Averbuch1 , Shun Fu Lee2,3, Urun Erbas Oz4,
Mamas A Mamas5 , James Louis Januzzi6 and Dennis T Ko7
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada; 2Department of Health Research Methods, Evidence, and Impact, McMaster University,
Hamilton, Ontario, Canada; 3Population Health Research Institute, Hamilton, Ontario, Canada; 4ICES, McMaster University, Hamilton, Ontario, Canada; 5Keele
Cardiovascular Research Group, Keele University, Keele, UK; 6Cardiology Division, Massachusetts General Hospital and Division of Heart Failure Trials, Baim Institute for
Clinical Research, Boston, MA, USA; 7Sunnybrook Health Sciences Centre and ICES, Toronto, Ontario, Canada
Abstract
Aims The LE index (Length of hospitalization plus number of Emergent visits ≤6 months) predicts 30 day all‐cause readmis-
sion or death following hospitalization for heart failure (HF). We combined N‐terminal pro‐B type natriuretic peptide (NT‐
proBNP) levels with the LE index to derive and validate the LENT index for risk prediction at the point of care on the day of
hospital discharge.
Methods and results In this prospective cohort sub‐study of the Patient‐centred Care Transitions in HF clinical trial, we used
log‐binomial regression models with LE index and either admission or discharge NT‐proBNP as the predictors and 30 day
composite all‐cause readmission or death as the primary outcome. No other variables were added to the model. We used re-
gression coefficients to derive the LENT index and bootstrapping analysis for internal validation. There were 772 patients
(mean [SD] age 77.0 [12.4] years, 49.9% female). Each increment in the LE index was associated with a 25% increased risk
of the primary outcome (RR 1.25, 95% CI 1.16–1.35; C‐statistic 0.63). Adjusted for the LE index, every 10‐fold increase in ad-
mission and discharge NT‐proBNP was associated with a 48% (RR 1.48; 95% CI 1.10, 1.99; C‐statistic 0.64; net reclassification
index [NRI] 0.19) and 56% (RR 1.56; 95% CI 1.08, 2.25; C‐statistic 0.64; NRI 0.21) increased risk of the primary outcome, respec-
tively. The predicted probability of the primary outcome increased to a similar extent with incremental LENT, regardless of
whether admission or discharge NT‐proBNP level was used.
Conclusions The point‐of‐care LENT index predicts 30 day composite all‐cause readmission or death among patients hospi-
talized with HF, with improved risk reclassification compared with the LE index. The performance of this simple, 3‐variable in-
dex ‐ without adjustment for comorbidities ‐ is comparable to complex risk prediction models in HF.
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Introduction
Patients hospitalized for heart failure (HF) represent a
high‐risk group faced with a 25% risk of readmission and a
4% risk of death within a month of discharge.1 Hospitaliza-
tions and readmissions account for 70% of the costs of HF
care.1 Among prognostic models developed to assess risk in
HF, only a small minority have been derived among
hospitalized2 patients, and most have used administrative
datasets3,4 rather than clinical variables at the point of care.
The LE index—a sum of Length of hospital stay and
number of Emergency department visits in the preceding
6 months—computed at the point of care on the day of
hospital discharge predicts 30 day composite all‐cause read-
mission or death with a 21% increase in risk per LE incre-
ment and with modest discrimination.5 N‐terminal pro‐B
type natriuretic peptide (NT‐proBNP), a prognostic bio-
marker in HF6 may improve performance of the LE risk pre-
diction index when measured on admission or discharge.
The change in NT‐proBNP concentrations from admission
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to discharge may also serve as an indicator of risk in the
month following hospitalization.6
In this sub‐study of the Patient Centered Transitions in
Heart Failure (PACT‐HF) randomized trial,7,8 we assess
whether admission, discharge, or change in NT‐proBNP from
admission to discharge improves performance of the LE risk
prediction index among patients hospitalized for HF. We de-
velop and internally validate a simple clinical scoring system
based on the LE index and NT‐proBNP concentrations to
predict the risk of 30 day composite all‐cause readmission
or death and 30 day all‐cause readmission.
Methods
Study population
The patients in this study were a subset enrolled in the
PACT‐HF multicentre cluster randomized trial7,8 who received
transitional care services during and after their hospitaliza-
tion, and had NT‐proBNP measured at hospital admission or
discharge (Figure 1). The trial complied with the Declaration
of Helsinki and was approved by the Research Ethics Boards
of all participating institutions with a waiver for written con-
sent but with informed verbal consent. The trial included
adult patients with an admission diagnosis of HF, confirmed
using the validated Boston criteria9 or using either BNP or
NT‐proBNP concentrations. We excluded patients who did
not meet diagnostic criteria for HF, who were previously ad-
mitted for HF during the study period, who died during hos-
pitalization, or who were discharged to other hospitals.
Data collection
We obtained patient clinical characteristics via review of hos-
pital charts and from administrative databases accessed at
ICES. Research personnel computed the LE index at the time
FIGURE 1 Flow diagram of the study participants. Of a total of 2494 patients in the PACT‐HF trial, 772 with NT‐proBNP measured at admission or dis-
charge were included in the sub‐study. NT‐proBNP was measured with a point‐of‐care device whose upper limit of detection was 9000 pg/mL.
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of discharge and measured NT‐proBNP levels at admission
and discharge during the index hospitalization using the
Cobas H 232© point‐of‐care NT‐proBNP testing kits supplied
by Roche diagnostics.10 We identified inpatient services
utilized using the Canadian Institute for Health
Information‐Discharge Abstract Database (CIHI‐DAD) and
deaths using the Ontario Registered Persons Database
(ORPD). The datasets were linked with unique identifiers
and were retrieved and analysed at ICES.
Outcomes
The primary outcome was 30 day composite all‐cause read-
mission or death. The secondary outcome was 30 day
all‐cause readmission.
Statistical analysis
Of the 772 patients, 182 (23.6%) had either missing admission
or missing discharge NT‐proBNP values (but not both). We
imputed missing admission or discharge NT‐proBNP values
using multiple imputation. We selected candidate variables
by matrix analysis11 and included sex, weight, creatinine,
history of atrial fibrillation, LVEF, discharge or admission NT‐
proBNP, and whether or not the patient was receiving di-
uretics, beta‐blockers, ACE inhibitors, or mineralocorticoid re-
ceptor antagonists. We summarized continuous variables
using means (SD) and medians (IQR) and categorical variables
using numbers and percentages. We compared continuous
variables using the Student’s t‐test or Wilcoxon two‐sample
test based on the distribution and categorical variables using
the χ2 or Fisher’s exact test.
We fitted log10‐binomial regression models with the LE
index as the predictor and either 30 day composite
all‐cause readmission or death or 30 day all‐cause readmis-
sion as the outcome with the percentage change in
NT‐proBNP from admission to discharge or either log10‐ad-
mission or log10‐discharge NT‐proBNP as a continuous covar-
iate. We adjusted all models for post‐discharge home care or
HF clinic services to account for differences in post‐discharge
care. We assessed risk with risk ratios (RR) and 95% confi-
dence intervals (CI). We assessed risk discrimination using
the C‐statistic and net reclassification index (NRI). The net re-
classification index was calculated relative to the LE index. We
assessed model goodness of fit with the Brier score,12 in
which a score of zero indicates perfect accuracy, while a score
of one indicates that the model is wholly inaccurate. We
internally validated the models using bootstrapping with
replacement from the original sample for 100 runs and
computed the optimistic C‐statistic and NRI. We computed
the additional points for the LE index to derive the LENT index
based on the coefficient estimates obtained from the models.
The predicted risk probability to each score of the LENT index
were estimated.
We conducted analyses using SAS Version 9.4 for UNIX
(SAS Institute Inc, Cary, NC, USA) and set the nominal signif-
icant level for testing at 5%.
We proposed a new scoring system based on the beta co-
efficients from the regression models with the LE index and
log‐transformed admission or discharge NT‐proBNP values
(Supporting Information, Table S1). The probability of
30 day outcomes associated with each point was calculated
using previously published methods.13
Results
Study population
The baseline characteristics of the 772 patients in the
derivation cohort are presented in Table 1, which details a
fairly typical higher risk population of hospitalized HF
patients. The mean age (SD) of the patients was 77.0 (12.4)
years, and 49.9% were female. The mean (SD) left ventricular
ejection fraction (LVEF) was 48% (14.5). Among the patients
in this study, 49.1% had diabetes, 42.1% had hypertension,
and 31.3% previously underwent percutaneous coronary in-
tervention (PCI) or coronary artery bypass grafting (CABG).
All of the patients in this study received in‐hospital transi-
tional care services, and 46.8% were referred for home care
or HF clinic services after discharge.
Outcomes
Of the 772 patients in the derivation cohort, 163 (21.1%)
were readmitted or died within 30 days of discharge and
157 (20.3%) were readmitted within 30 days of discharge.
At baseline, the mean (SD) LE index was 7.4 (2.1) for patients
who were readmitted or died within 30 days, and 6.5 (1.8) for
patients who were neither readmitted nor died within 30 days
(Table 1).
30 day all‐cause readmission or death
Each increment in the LE index was associated with a 25%
increased risk of 30 day composite all‐cause readmission or
death (RR 1.25; 95% CI 1.16, 1.35 per unit) with moderate
discrimination (C‐statistic 0.63; 95% CI 0.58, 0.68). The LE
index was well calibrated for 30 day composite all‐cause read-
mission or death (Brier score 0.16). On its own, log10‐admis-
sion NT‐proBNP had suboptimal discrimination for 30 day
composite all‐cause readmission or death (C‐statistic 0.58;
95% CI 0.53, 0.63), as did log10‐discharge NT‐proBNP (C‐sta-
tistic 0.57; 95% CI 0.52, 0.62) (Table 2).
After adjusting for the LE index, every 10‐fold increase in
admission NT‐proBNP was associated with a 48% increased
Van Spall LENT risk prediction index for HF 3
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.13109
risk of 30 day composite all‐cause readmission or death (RR
1.48; 95% CI 1.10, 1.99), and every 10‐fold increase in
discharge NT‐proBNP was associated with a 56% increased
risk of 30 day composite all‐cause readmission or death (RR
1.56; 95% CI 1.08, 2.25). The addition of admission or
discharge NT‐proBNP to the LE index correctly reclassified
12% or 20% of events, respectively, and 7% or 1% of non‐
events, respectively. Risk classification for 30 day composite
all‐cause readmission or death was significantly improved
with log10‐admission (NRI 0.19; 95% CI 0.02, 0.36) and
log10‐discharge NT‐proBNP (NRI 0.21; 95% CI 0.04, 0.38)
relative to the LE index alone. In contrast, the percentage
change in NT‐proBNP from admission to discharge was not
associated with increased risk of 30 day composite all‐cause
readmission or death (RR 1.00, 95% CI 1.00, 1.00; NRI 0.07;
95% CI 0.10, 0.23; Brier score 0.16) relative to the LE index
(Table 2).
30 day all‐cause readmission
After adjusting for post‐discharge transitional care services
that were delivered during the trial, increments in the LE
index were associated with a 26% increased risk of 30 day
all‐cause readmission (RR 1.26; 95% CI 1.16, 1.36 per unit)
with moderate discrimination (C‐statistic 0.63; 95% CI 0.58,
0.68). The LE index was well calibrated for 30 day all‐cause re-
admission (Brier score 0.15). The log10‐admission NT‐proBNP
poorly predicted 30 day all‐cause readmission on its own (C‐
statistic 0.58; 95% CI 0.53, 0.63). The log10‐discharge
NT‐proBNP performed similarly for 30 day all‐cause readmis-
sion (C‐statistic 0.57; 95% CI 0.52, 0.63) (Table 2).
After adjusting for the LE index, each 10‐fold increase in
admission NT‐proBNP was associated with a 43% increased
risk of 30 day all‐cause readmission (RR 1.43; 95% CI 1.06,
1.93), and each 10‐fold increase in discharge NT‐proBNP
was associated with a 55% increased risk of 30 day all‐cause
readmission (RR 1.55; 95% CI 1.06, 2.25). Log10‐discharge
NT‐proBNP significantly improved risk classification with the
LE index for 30 day all‐cause readmission (NRI 0.20; 95% CI
0.03, 0.37 compared with the LE index); log10‐admission
NT‐proBNP improved risk classification without statistical
significance (NRI 0.15; 95% CI 0.03, 0.32 compared with
the LE index). The addition of admission or discharge
NT‐proBNP to the LE index correctly reclassified 8% or 20%
of events, respectively, and 6% or 0% of non‐events, respec-
tively. After adjusting for the LE index, the percentage change
in NT‐proBNP from admission to discharge was not associ-
ated with 30 day all‐cause readmission (RR 1.00; 95% CI
1.00, 1.00; NRI 0.04; 95% CI 0.13, 0.21; Brier score 0.15)
(Table 2).
LENT index scoring system
The scoring system for the LENT index, ranging from 2 to 13,
and the option of using admission or discharge NT‐proBNP
values to compute the LENT indices is depicted in the
Table 1 Baseline characteristics of patients and 30 day outcomes (N = 772)
Readmitted or dead in 30 days
(N = 163)
Neither readmitted nor dead in 30 days
(N = 609)
P‐
value
Demographics
Age (year), mean (SD) 77.4 (12.5) 76.9 (12.4) 0.68
Sex, n (%)
Male 81 (49.7) 306 (50.2) 0.90
Female 82 (49.3) 303 (49.8)
Resides in long‐term care, n (%) 15 (9.2) 38 (6.2) 0.51
Co‐morbidities
LV ejection fraction, mean (SD) 48.5 (14.4) 47.9 (14.5) 0.61
Hypertension, n (%) 65 (39.9) 260 (42.7) 0.52
Diabetes, n (%) 79 (48.5) 300 (49.3) 0.86
Diabetes with end organ damage, n (%) 76 (46.6) 281 (46.1) 0.91
Prior PCI or CABG, n (%) 64 (39.3) 178 (29.2) 0.01
Chronic pulmonary disease, n (%) 22 (13.5) 74 (12.2) 0.64
Dementia, n (%) 12 (7.4) 28 (4.6) 0.16
Cancer (any), n (%) 8 (4.9) 12 (2.0) 0.04
Resource utilization
Acuity of admission (via emergency department), n
(%)
161 (98.8) 607 (99.7) 0.16
Number of ED visits in preceding 6 months, mean
(SD)
3.2 (2.7) 2.2 (1.6) <0.01
Estimated risk
LE index, mean (SD) 7.4 (2.1) 6.5 (1.8) <0.01
Admission NT‐proBNP (pg/mL), median (IQR) 4569 (2686, 10 030) 3702 (1970, 6821) <0.01
Discharge NT‐proBNP (pg/mL), median (IQR) 2631 (1285, 4880) 2073 (1057, 3630) 0.02
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graphical abstract. The distribution of the LENT index is
depicted in Figure 2.
30 day all‐cause readmission or death
The admission and discharge LENT indices offered moderate
discrimination for 30 day composite all‐cause readmission
or death (C‐statistic 0.64; 95% CI 0.59, 0.69 for both) with
good calibration (Brier score 0.16 for both). The correspond-
ing predicted probabilities of 30 day composite all‐cause re-
admission or death is shown in the graphical abstract. Using
admission NT‐proBNP, the lowest and highest possible LENT
score was associated with a mean probability (SD) of 0.05
(0.00) and 0.51 (0.01), respectively, for 30 day readmission
or death. Using discharge NT‐proBNP, the lowest and highest
LENT score was associated with a mean probability (SD) of
0.06 (0.00) and 0.53 (0.01), respectively, for 30 day readmis-
sion or death (Figure 3, Supporting Information, Table S2).
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FIGURE 2 The distribution of LENT index scores in the cohort of patients
hospitalized for HF. The distribution of admission and discharge LENT
scores was similar.
FIGURE 3 The predicted probability of 30 day composite all‐cause read-
mission or death in patients hospitalized for HF. The LENT indices demon-
strate a continuum of risk, with higher scores associated with an
increased risk of 30 day composite all‐cause readmission or death.
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30 day all‐cause readmission
The admission and discharge LENT indices offered moderate
discrimination for 30 day all‐cause readmission (C‐statistic
0.64; 95% CI 0.59, 0.69 for both) with good calibration (Brier
score 0.15 for both). Using admission NT‐proBNP, the lowest
and highest possible LENT score was associated with a
probability (SD) of 0.06 (0.00) and 0.46 (0.01), respectively,
for 30 day readmission. The LENT index using discharge
NT‐proBNP offered similar results, with the lowest and
highest scores associated with a probability (SD) of 0.06
(0.00) and 0.48 (0.01), respectively, for 30 day readmission
(Figure 4, Supporting Information, Table S3).
Internal validation
30 day all cause readmission or death
In the internal validation with 100 bootstrap samples, the LE
index had moderate discrimination for 30 day composite
all‐cause readmission or death (optimistic C‐statistic 0.63;
95% CI 0.59, 0.68). Risk classification for 30 day composite
all‐cause readmission or death was improved with the
LENT index using admission NT‐proBNP (optimistic NRI
0.16; 95% CI 0.00, 0.34; optimistic C‐statistic 0.64; 95%
CI 0.60, 0.69) and discharge NT‐proBNP (optimistic NRI
0.19; 95% CI 0.02, 0.37; optimistic C‐statistic 0.64; 95%
CI 0.59, 0.69).
30 day all cause readmission
In the internal validation with 100 bootstrap samples, the LE
index had moderate discrimination for 30 day all‐cause read-
mission (optimistic C‐statistic 0.64; 95% CI 0.59, 0.69). Rela-
tive to the LE index, risk classification for 30 day all‐cause
readmission was improved with the LENT index using admis-
sion (optimistic NRI 0.15; 95% CI 0.00, 0.33; optimistic
C‐statistic 0.64; 95% CI 0.60, 0.69) and discharge NT‐proBNP
(optimistic NRI 0.18; 95% CI 0.00, 0.37; optimistic C‐statistic
0.64; 95% CI 0.60, 0.69).
Discussion
In this multicentre study of patients being discharged after
hospitalization for HF, we derived a risk index that predicts
30 day clinical outcomes using only length of stay, number
of ED visits in the preceding 6 months, and admission or
discharge NT‐proBNP (Figure 5 ). Ten‐fold increases in NT‐
proBNP were associated with increased risk of 30 day com-
posite all‐cause readmission or death and 30 day all‐cause
readmission relative to the LE index, a simple bedside index
which compares favourably to more complex risk prediction
models in HF.5 The 3‐variable LENT index correctly identified
a greater proportion of both events and non‐events in
patients hospitalized for HF relative to the LE index.
The simplicity of the LENT index and its derivation at the
bedside offer major advantages over existing risk prediction
FIGURE 4 The predicted probability of 30 day all‐cause readmission in
patients hospitalized for HF. The LENT indices demonstrate a continuum
of risk, with higher scores associated with an increased risk of 30 day
all‐cause readmission.
FIGURE 5 The LENT risk index and its performance in an internally validated sample.
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models. The LENT index does not require adjustment for base-
line or clinical characteristics, improving its generalizability
and ease‐of‐use in clinical practice without sacrificing
performance; in our previous comparison of the LE index5
with the more complex LACE index (which includes
additional variables for acuity of presentation and Charlson
co‐morbidity),14 we found no difference in risk discrimination
between the two for the outcome of 30 day composite
all‐cause readmission or death. Like the LACE index, a majority
of validated risk prediction models in HF are derived and
validated in administrative claims databases and use
large numbers of variables that make computation difficult
and limit their utility at the point of care. For example,
the Medicare‐endorsed readmission risk score (RRS) includes
37 variables from an administrative claims database, and
the Get With The Guidelines risk calculator includes up to
28 points each for categories of age, blood pressures, and
BUN.3
The discrimination of the LE index and the LENT index was
similar; however, the net reclassification index improved with
the addition of NT‐proBNP to the LE index. These disparate
findings can be explained by the limitations of using the dif-
ference in C‐statistics to assess the incremental value of pre-
dictors. The C‐statistic is defined as the probability that for a
given predictive model, individuals with an event will have
a higher predicted risk than those who do not experience
an event; it is not the probability that individuals are correctly
classified as high or low risk.15 By contrast, the NRI is the
sum of the percentage of events and non‐events correctly
reclassified less the percentage of events and non‐events
incorrectly reclassified by the addition of a predictor to
a model.16 This distinction is clinically relevant; if a patient
is reclassified as having higher or lower risk by adding a
predictor to a basic model, clinicians can allocate post‐
discharge resources and formulate follow‐up care plans
accordingly.17
To date, there are no risk models that predict 30 day
composite all‐cause readmission or death or 30 day
all‐cause readmissions in patients admitted for HF with
C‐statistics >0.65, which reveals the challenges of predicting
readmission, in particular. The LENT index had moderate
discrimination (C‐statistic 0.64; 95% CI 0.59, 0.69 for 30 day
composite all‐cause readmission and death and for 30 day
all‐cause readmission) that is comparable or better than
other models such as the RRS, validated in a separate sample
(C‐statistic 0.62; 95% CI 0.55, 0.68 for 30 day composite
all‐cause readmission or death; C‐statistic 0.61; 95% CI 0.55,
0.67 for 30 day all‐cause readmission).14 In a study of
59 652 patients admitted for HF, a model containing length
of stay, age, Charlson co‐morbidity index, and emergency
visits offered modest discrimination for 30 day composite
readmission or death (C‐statistic 0.61).18 Similarly, in a study
of 24 326 patients admitted for HF, a more complicated
model consisting of discharge BNP, co‐morbidities, patient
demographics, and year hospitalized achieved moderate dis-
crimination for 30 day all‐cause readmission (C‐statistic
0.63).19
The discrimination of models for all‐cause readmission is
typically lower than that of HF‐specific readmission,20 as up
to 65% of readmissions after HF hospitalization are for
reasons other than HF.21 Readmission may be more difficult
to predict in HF than mortality due to unaccounted for
patient‐level and health systems variables that are challeng-
ing to measure and incorporate in risk prediction models.22
Both admission and discharge NT‐proBNP added incre-
mental value to the LE index for predicting 30 day all‐cause
readmission or death, but on their own, were suboptimal in
predicting risk or discriminating between risk groups. NT‐
proBNP, a biomarker that is sensitive to changes in LV filling
pressure, may be more useful in predicting HF‐specific, rather
than all‐cause, endpoints. While NT‐proBNP has previously
been shown to add incremental value to clinical risk
prediction models,19 there are few studies on its utility for
30 day outcomes. Our study is one of the first to combine
NT‐proBNP with simple variables based on health care utiliza-
tion to predict 30 day all‐cause readmission or death.
Our study has multiple strengths. This was a pragmatic,
multicentre trial with broad inclusion criteria, resulting in a
study sample representative of real‐world patients hospital-
ized for HF: elderly, multi‐morbid, and an equal distribution
of male and female patients. The diagnosis of HF was
confirmed by a research nurse using the validated Boston
criteria, rather than administrative data in which diagnoses
may be misclassified.23 All patients received standard
post‐discharge services, and we adjusted the regression
models for level of transitional care support, which can im-
pact 30 day outcomes but which are typically not accounted
for in other risk prediction models. We internally validated
our risk index via bootstrapping. The LENT index can be easily
computed at the bedside without chart review, improving its
clinical utility.
Limitations
A major limitation of this study was the lack of a complete
range of NT‐proBNP values due to technical limitation of
point‐of‐care devices. Values higher than 9000 μg/mL were
recorded as “>9000” on the devices and analysed as 9000.
It is possible that a complete range would have yielded a
LENT index with a better performance than observed in the
study. The performance of the LENT index will require testing
in an external validation cohort using devices that can cap-
ture a broader range of NT‐proBNP values. Furthermore,
the 30 day all‐cause mortality rate observed was lower
than expected.2 However, as discrimination for mortality is
typically better than for readmission, the discrimination
of the LENT index for 30 day composite all‐cause readmission
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or death is likely underestimated due to the low mortality.
Finally, the LENT index was derived among hospital
inpatients, and its performance among those in ambulatory
day hospital or home intravenous diuretic programmes is
unclear.
Conclusions
The point‐of‐care LENT index—based on length of hospital
stay, number of ED visits in preceding 6 months, and either
admission or discharge NT‐proBNP levels—is a practical and
reliable means of estimating the risk of 30 day composite
all‐cause readmission or death or 30 day all‐cause readmis-
sion following hospitalization for HF. The performance of this
simple index is comparable with more complex risk prediction
models derived from administrative datasets and may im-
prove the ability of clinicians to identify high‐risk patients
and allocate resources accordingly.
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